Glyko gets grant for lysosomal storage diseases tests:
This article was originally published in Clinica
Glyko Biomedical has been awarded a Phase II small business innovative research grant to develop a second-generation diagnostic test system for the group of inherited metabolic disorders called lysosomal storage diseases. The grant, from the National Institute of Child Health and Human Development, is just under $600,000 over two years. Glyko, based in Novato, California, estimates there are more than 35 lysosomal storage diseases, which affect over 30,000 people in the US.
You may also be interested in...
Azar says ACIP’s prioritization recommendations should carry weight, but states will be final arbiter of who is vaccinated.
Sanofi R&D head John Reed says the company has kept 95% of patients on its nearly 400 clinical trials, started 59 studies, and benefited from its in-house drug supply management.
The funding will be used to support clinical and preclinical development at its portfolio companies, with 8-10 programs in the clinic in 2021.